CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17–Mediated Psoriasiform Skin Inflammation In Vivo

Mark Mellett1,4, Barbara Meier1, Deepa Mohanan1, Rebekka Schairer2, Phil Cheng1, Takashi K. Satoh1, Betina Kiefer1, Caroline Ospelt3, Stephan Nobbe1, Margot Thome2, Emmanuel Contassot1 and Lars E. French1,4

Rare autosomal dominant mutations in the gene encoding the keratinocyte signaling molecule CARD14, have been associated with an increased susceptibility to psoriasis, but the physiological impact of CARD14 gain-of-function mutations remains to be fully determined in vivo. Here, we report that heterozygous mice harboring a CARD14 gain-of-function mutation (Card14ΔE138) spontaneously develop a chronic psoriatic phenotype with characteristic scaling skin lesions, epidermal thickening, keratinocyte hyperproliferation, hyperkeratosis, and immune cell infiltration. Affected skin of these mice is characterized by elevated expression of anti-microbial peptides, chemokines, and cytokines (including T helper type 17 cell-signature cytokines) and an immune infiltrate rich in neutrophils, myeloid cells, and T cells, reminiscent of human psoriatic skin. Disease pathogenesis was driven by the IL-23/IL-17 axis, and neutralization of IL-23p19, the key cytokine in maintaining T helper type 17 cell polarization, significantly reduced skin lesions and the expression of antimicrobial peptides and proinflammatory cytokines. Therefore, hyperactivation of CARD14 alone is sufficient to orchestrate the complex immunopathogenesis that drives T helper type 17-mediated psoriasis skin disease in vivo.


INTRODUCTION
Psoriasis is a common chronic inflammatory disease of the skin that is estimated to affect approximately 2% of the global population and is equally prevalent in males and females (Christophers, 2001; Gudjonsson and Elder, 2007). Psoriasis is characterized by scaly erythematous plaques on the skin, which, given its chronic course, significantly impairs the quality of life of affected individuals. The most common form of psoriasis is psoriasis vulgaris (plaque psoriasis), but other forms exist with distinct clinical features, including guttate psoriasis, pustular psoriasis, and palmoplantar psoriasis (Griffiths and Barker, 2007). Overall, 20–30% of plaque psoriasis cases are associated with debilitating psoriatic arthritis, and psoriasis patients can suffer from comorbidities including cardiovascular disease, diabetes, and obesity (Griffiths and Barker, 2007; Mease et al., 2013). Histological hallmarks of psoriasis include epidermal acanthosis, keratinocyte hyperproliferation, hyperkeratosis, cutaneous immune cell infiltration, and angiogenesis. Disease symptoms arise from a complex interaction between keratinocytes and infiltrating immune cells (Bos and De Rie, 1999; Boyman et al., 2007; Sano et al., 2005; Valdimarsson et al., 1995). However, the early triggers that lead to full-blown disease are not well understood, confounded by the wide range of genetic factors that contribute to an elevated risk of developing psoriasis, including genes controlling epidermal barrier integrity (e.g., LCE3B, LCE3D) and antigen presentation (e.g., HLA-Cw*0602, ERAP1) and genes of the innate (e.g., NFKBIA) and adaptive immune systems (e.g., IL12B, IL23R) (Tsui et al., 2012). Although genome-wide association studies have shown that approximately more than 80 genes in Caucasian and Han Chinese populations are associated with an increased susceptibility to psoriasis, very few genetic variants have actually been studied in vivo (Sheng et al., 2014; Tsui et al., 2017).

Rare autosomal dominant mutations in the gene encoding a keratinocyte scaffold molecule, CARD14 (which maps to the PSORS2 locus) have been associated with a number of psoriatic phenotypes including plaque psoriasis and psoriatic arthritis, generalized pustular psoriasis, and palmoplantar pustular psoriasis, in addition to familial and sporadic cases of the clinically related but rare disease pityriasis rubra pilaris (PRP) (Fuchs-Telem et al., 2012; Has et al., 2016; Hong et al., 2014; Jordan et al., 2012a, 2012b; Li et al., 2015; Moseen et al., 2015; Sugiuara et al., 2014; Takeichi et al., 2017a, 2017b). CARD14 is a proinflammatory signaling molecule whose expression is predominantly restricted to the placenta and keratinocytes of the skin, although CARD14 expression was also reported on CD31-positive endothelial cells (Fuchs-Telem, 2012; Harden et al., 2014). CARD14 is the second...
RESULTS

CARD14 Gof mutation causes spontaneous signalosome formation in primary human keratinocytes, which is dependent on a functional CARD domain

Consistent with previous reports, CARD14 E138A and ΔE138 mutants both caused enhanced NF-κB and AP-1 activation in vitro in HEK293 cells compared with wild-type (WT) CARD14, with the E138A mutant showing a more potent response (see Supplementary Figure S1a online) (Afonina et al., 2016; Li et al., 2015). CARD14 E138A and CARD14 ΔE138 GoF mutants were also overexpressed in primary keratinocytes and HEK293 cells and were observed to interact with endogenous Bcl10 by co-immunoprecipitation (Figure 1a, and see Supplementary Figure S1b), whereas Bcl10 interaction with CARD14 WT was below detectable levels. Because this was contrary to previous findings (Afonina, 2016; Scudiero, 2011), we sought to assess other means of CARD14 activity. There was a reduction of Bcl10 expression observed in the presence of all three CARD14 constructs in HEK293 cells (see Supplementary Figure S1b) and a decrease of CARD14 mutant expression in primary keratinocytes (Figure 1a). Previously, it has been suggested that CARD14 mutants associated with psoriasis are less soluble than WT CARD14 (Berki et al., 2015). Additionally, it has been previously described that Bcl10 forms oligomeric structures that can be nucleated by CARD11 (Qiao et al., 2013). It was therefore of interest to determine whether interaction of CARD14 with Bcl10 can induce nucleation and insolubility of the latter. First, we assessed whether mutation of the CARD14 CARD domain could diminish downstream effects. The CARD14 R38 residue has been previously described to be at the Bcl10-interacting interface, and substitution of arginine R38 with cysteine in the CARD domain was previously reported to lack the ability to activate NF-kB (Jordan, 2012b; Qiao, 2013); therefore, it was anticipated that the R38C mutation would abolish CARD:CARD interactions. Indeed, mutation of the R38 residue in the CARD14 E138A construct completely abrogates the ability of the E138A mutant to interact with Bcl10 (see Figure 1b, Supplementary Figure S1c) and to potententially activate NF-kB and AP-1 in HEK293 cells (see Supplementary Figure S1d). R38C mutation also diminished the ability of CARD14 E138A to drive IL-8 production in primary keratinocytes (see Supplementary Figure S1e).

To assess nucleation of Bcl10 in the presence of CARD14 GoF mutants, primary keratinocytes were transfected with CARD14 WT, CARD14 E138A, and CARD14 R38C/E138A. Cells were lysed in Triton X-100—containing buffer (Sigma Aldrich, St. Louis, MI), and Triton-insoluble and soluble fractions were assessed by SDS-PAGE. As expected, mutant CARD14 variants were found at higher levels in the insoluble fraction than WT CARD14. Moreover, levels of Bcl10 were more highly increased in the insoluble fraction in the presence of CARD14 E138A compared with CARD14 WT, and this was dependent on a functional CARD domain (Figure 1c), also consistent with a previous report (Bertin et al., 2001).

Insoluble mutant CARD14 E138A and CARD14 ΔE138/Bcl10 complexes or “signalosomes” are visible by confocal microscopy in primary keratinocytes (Figure 1d), whereas CARD14 WT was more widely expressed throughout the cytoplasm, consistent with its weak interaction with Bcl10 in co-immunoprecipitation studies. CARD14 R38C/E138A retained the ability to form insoluble oligomers (Figure 1c and d), but it failed to recruit Bcl10 to these complexes in primary keratinocytes (Figure 1d).

Spontaneous signalosome formation induced by CARD14 E138A and CARD14 ΔE138 resulted in enhanced Malt1 para-caspase activity in HEK293 cells, as measured using a previously described fluorescence resonance energy transfer-
Figure 1. Mutation of Card14 E138 causes spontaneous signalosome assembly in primary keratinocytes and is dependent on a functional CARD domain. (a, b) Primary keratinocytes were transfected with Myc-tagged CARD14 WT, CARD14 E138A, and (a) CARD14 ΔE138 or (b) CARD14 R38C/E138A for 24 hours. Cell lysates were immunoprecipitated with an anti-Bcl10 antibody, followed by immunoblotting with indicated antibodies. (c) Human primary keratinocytes were transfected for 24 hours with Myc-tagged CARD14 WT, CARD14 E138A, or CARD14 R38C/E138A. Cells were lysed in Triton X-100-containing buffer, and soluble and insoluble fractions were subjected to SDS-PAGE followed by immunoblotting with indicated antibodies. (d) Human primary keratinocytes were transfected for 24 hours with Myc-tagged CARD14 WT, CARD14 E138A, CARD14 ΔE138, or CARD14 R38C/E138A and visualized for expression and localization by confocal microscopy using specific anti-Myc and anti-Bcl10 antibodies. Nuclei were stained with DAPI. Scale bar = 15 μm. (e) Flow cytometry analysis and immunoblot analysis of HEK293T cells transfected with increasing amounts of Myc-tagged CARD14 constructs with Strep-tagged Malt1 and the...
based assay (Pelzer et al., 2013) (Figure 1e), consistent with previous reports (Afonina, 2016; Howes, 2016). Malt1 displayed augmented catalytic activity in the presence of CARD14 E138A and CARD14 ΔE138 mutants compared with WT (Figure 1e). However, CARD14 R38C/E138A lost the ability to stimulate Malt1 activity beyond basal levels. In primary keratinocytes, CARD14 E138A and CARD14 ΔE138 mutants drive production of IL-36g; however, again
disruption of the CARD domain abolishes this effect (Figure 1f).

**Mutation of Card14 E138 causes spontaneous psoriasiform disease in mice**

To define the physiological impact of CARD14 E138 GoF mutation in potentially driving psoriasis pathogenesis, a transgenic mouse incorporating deletion of the E138 residue of CARD14 was generated using CRISPR/Cas9 technology (see Supplementary Figure S2a and b). The Card14ΔE138 mutation was chosen because it displayed less potent activation of NF-κB, and it was speculated that these mice might be less likely to suffer unwanted defects due to hyperactive NF-κB activity. Card14ΔE138 heterozygous mice appeared indistinguishable from WT littermates at birth (see Supplementary Figure S2c) but developed dry flaky skin patches on the back at 5 days of age, which began to disappear at 7 days. However, this progressed to the development of thickened squamous skin on the tail (between 2 and 3 weeks) and, finally, the ears (at 4–5 weeks), reminiscent of human psoriasis skin lesions (see Supplementary Figure S2d and e). Adult mice showed a chronic psoriatic phenotype with thickened squamous skin of the ears and tail and dry skin around the eyes and whiskers, affecting 100% of heterozygous male and female mice (Figure 2a). Ear thickness was significantly increased in Card14ΔE138+/− mice compared with WT littermates (Figure 2b). There was no significant difference in weight in Card14ΔE138+/− adult mice compared with WT littermates (Figure 2c).

Hematoxylin and eosin staining of ear tissue from Card14ΔE138+/− mice showed acanthosis due to keratinocyte hyperproliferation and immune cell infiltration of the
skin (Figure 2d), areas of hyperkeratosis (Figure 2e), including parakeratosis (arrow) and orthokeratosis (arrowhead), and keratotic follicular plugging (see Supplementary Figure S3a online), all hallmarks of human psoriatic skin disease. Similarly, tail skin showed marked hyperplasia (see Supplementary Figure S3b) with increased thickening of the epidermis and immune cell infiltration. In addition to a clear increase in infiltrate of immune cells, the presence of microabscesses was also observed in the epidermis of Card14E138+/− mice (Figure 2f). Positive staining with the neutrophil marker Ly6G indicated that neutrophils make up the composition of these microabscesses (Figure 2g). An increased number of enlarged CD31-positive blood vessels were also histologically observed in the dermis, indicating an increase in the dermal vasculature in psoriatic tissue from Card14E138+/− mice (Figure 2h, and see Supplementary Figure S3c). In Card14E138+/− mice, basal keratinocytes showed strong and abundant expression of the proliferation marker Ki67, indicating hyperproliferation of keratinocytes in the basal layer (Figure 2i, and see Supplementary Figure S3d). Similarly, keratin-14 expression, a marker for the proliferative basal layer of the epidermis, was no longer restricted to basal keratinocytes, as in WT mice, but also present in suprabasal layers, typical of human psoriasis. Expression of keratin-1 (an indicator of early keratinocyte differentiation), which was localized in the suprabasal layer of WT mice, is increased and expressed throughout the epidermis in Card14E138+/− mouse skin. Card14E138 homozygous mice displayed development abnormalities (see Supplementary Figure S4a online) and increased mortality. Surviving neonates were runts (see Supplementary Figure S4b) and died after a few days, typically with a very marked psoriatic phenotype (see Supplementary Figure S4c and d). Toluídine blue staining was performed to determine whether neonates had a skin barrier defect and an increase in skin permeability. Toluídine blue dye failed to stain the epidermis, indicating that neither homozygous nor heterozygous pups had an epidermal barrier defect (see Supplementary Figure S4e).

CARD14 Gof mutation in vivo results in a transcriptomic gene profile similar to human plaque psoriasis

To obtain a comprehensive overview of the transcriptional signature of the inflammatory milieu driving disease pathogenesis in Card14E138+/− mice, RNA was extracted from ear tissue of 5-week-old mice and subjected to RNA sequencing analysis (Figure 3a−c). Differentially expressed genes from the psoriatic tissue of Card14E138+/− mice included up-regulated hyperproliferative keratins (Krt6a, Krt6b, Krt16b); antimicrobial peptides including β-defensins (Defb3, Defb4, Defb14), S100 proteins (S100a7, S100a8, S100a9), and lipocalin-2 (Lcn2); and mRNA-encoding cytokines of the innate (IL-1α, IL-1β, IL-16, IL-36β, IL-36γ, IL-6, and IL-17C) and adaptive (IL-20, IL-22, IL-23p19, and IL-17F) immune systems. IL-20 family member IL-19, a cytokine previously shown to be up-regulated in serum and tissue of psoriasis patients and a key component of the IL-23/IL-17A axis, was one of the most highly up-regulated cytokines. IL-19 was shown previously to be specifically expressed by keratinocytes and acts in an autocrine manner in synergy with IL-17A to further enhance induction of anti-bacterial S100 proteins (Romer et al., 2003; Witte et al., 2014). Up-regulation of chemokines was also evident, including Ccl20 and the neutrophil chemotactants Cxcl1, Cxcl2, Cxcl3, and Cxcl5. This transcriptional signature likely also reflects secondary changes in dermal endothelial cells and infiltrating immune cells. IL-1 family cytokines, including receptor antagonists, NOD2, caspase-1, caspase-4, and NLRP3, are all up-regulated in Card14E138+/− psoriatic tissue, indicating that this phenotype is very much dependent on auto-inflammatory and autoimmune networks.

Psoriatic tissue from Card14E138+/− mice also showed high expression of early cornified envelope proteins including involucrin (Iv) and IL-17A-induced small proline rich proteins (Sprr2b and Sprr2d). The S100-interacting protein Fabp5 is also increased. Late cornified envelope proteins including Lce3b and Lce3d show high expression, and the serine protease inhibitors Sepinb3a, Sepinb3c, and Sepina9 are also highly up-regulated. Down-regulated differentially expressed genes include keratin-2 and -24, serpin3b, and serpin12. Filaggrin-2 was also down-regulated, inversely correlating with filaggrin-1 expression in this model. IL-38 (Ilf10), an anti-inflammatory cytokine that specifically inhibits IL-36 cytokines, was also down-regulated in Card14E138+/− psoriatic tissue, suggesting that in psoriatic skin disease, increased activity of IL-36 cytokines is likely additionally enhanced by decreased expression of this endogenous inhibitor.

We performed pathway analysis and found that keratinization, formation of the cornified envelope, signaling by interleukins, and antimicrobial peptides were enriched functions among up-regulated genes (Figure 3c). Comparing transcriptome analysis from Card14E138+/− mice with that of human plaque psoriasis available from the publications of Li et al. (2014) (GSE54456) and Keermann et al. (2015) (GSE6651), there is positive enrichment of up-regulated genes with both human studies and negative enrichment of down-regulated genes (Figure 3d). This correlation shows that the transcriptional landscape induced by CARD14 Gof mutation in vivo is typical of human plaque psoriasis.

To further confirm transcriptomic data and to analyze the expression of proinflammatory genes at the onset of macroscopic skin changes in Card14E138+/− mice, RNA was extracted from ear tissue of 5-week-old Card14E138+/− mice and analyzed by quantitative PCR. Expression of mRNA encoding the proinflammatory cytokines IL-36γ, IL-1β, IL-17C, and IL-19 (Figure 3e) was significantly higher in ear tissue of Card14E138+/− mice. Similar to human psoriatic skin, Card14E138+/− murine tissue showed strong and significantly increased expression of genes encoding the S100 antimicrobial peptides S100a7 and S100a8 (Figure 3f); β-defensins Defb3, Defb4, and Defb14 (Figure 3g); and the chemokines Cxcl1, Cxcl2, and Cccl20 (Figure 3h). Expression of filaggrin-1 and filaggrin-2 was also assessed and confirmed RNA sequencing data, with an increase in filaggrin-1 (Flg) and a decrease in filaggrin-2 (Flg2) in psoriatic tissue (Figure 3i). Expression of caspase-14, which mediates filaggrin processing to form the cornified envelope, is also increased in Card14E138+/− psoriatic tissue (Figure 3a and b). Loss of filaggrin-1 expression is associated with an
Figure 3. Transcriptome analysis of psoriatic tissue from ears of Card14ΔE138−/− mice shows a gene signature typical of human plaque psoriasis. (a–d) RNA was extracted from 8-week-old Card14ΔE138−/− heterozygous mice and wild-type littermates and subject to RNA sequencing analysis. (a) Heatmap showing the 542 genes DEGs between three replicates of Card14ΔE138−/− heterozygous mice and wild-type littermates. (b) Volcano plot showing the threshold for significant genes from Card14ΔE138−/− versus wild-type mice. A threshold of false discovery rate < 0.05 and log2 ratio > 2 or < −2 was chosen. Differentially expressed genes of particular interest are labeled. (c) Dotplot showing the significantly enriched pathways from the Reactome. Each dot size represents the
Card14 Mutation in Mice Drives Psoriasiform Disease

M Mellett et al.

CARD14 Mutation in Mice Drives Psoriasiform Disease

epidermal barrier dysfunction, which grants microbes the means to invade the epidermis, as in atopic dermatitis (O’Regan et al., 2008). Robust expression of filaggrin-1 in psoriatic tissue of Card14ΔE138+/− mice is consistent with the lack of any barrier defect in these mice (Figure 3j).

The CARD14/Bcl10 signaling axis is hyperactive in primary keratinocytes from Card14ΔE138+/− mice

To determine whether the epidermal changes observed in Card14ΔE138+/− mice were due to dysregulated CARD14 function, epidermal tissue from ear pinnae of WT and Card14ΔE138+/− mice were stained for Bcl10 and CARD14 expression. Both molecules showed enhanced expression in the epidermis from Card14ΔE138+/− mice compared with WT (Figure 4a). To further assess the CARD14/Bcl10 interaction in Card14ΔE138+/− mice, primary keratinocytes were isolated from WT and Card14ΔE138+/− mouse epidermis and cultured ex vivo. Murine keratinocytes were subject to lysis in Triton X-100-containing lysis buffer and soluble and insoluble fractions subject to SDS-PAGE (Figure 4b). CARD14 and Bcl10 showed increased expression in the insoluble fraction in Card14ΔE138+/−-derived cells compared with WT control cells, which correlated with decreased expression in the soluble fraction. Additionally, Bcl10 and CARD14 showed increased interaction as determined by co-immunoprecipitation (Figure 4c) and enhanced processing of Malt1 substrate protein RelB. Bcl10 expression was visualized by confocal microscopy, and in primary keratinocytes from WT mice, Bcl10 was expressed uniformly throughout the cytoplasm; however, in keratinocytes from Card14ΔE138+/− mice Bcl10 was observed in discrete signalingosome structures (Figure 4d). To assess the downstream effects of this increased interaction, transcript levels of pro-inflammatory molecules were assessed in keratinocytes isolated and cultured from WT and Card14ΔE138+/− mouse epidermis by quantitative PCR. Levels of mRNA encoding S100A7, IL-17C, IL-19, and IL-36γ were significantly increased in Card14ΔE138+/− keratinocytes compared with WT cells (Figure 4e).

Neuronalization of the T helper type 17-polarizing cytokine IL-23 p19 subunit attenuates disease symptoms

We next characterized the immune infiltrate of the skin of Card14ΔE138+/− mice. Psoriatic skin of Card14ΔE138+/−/−
Figure 4. Keratinocytes from Card14ΔE138+/− mice display enhanced CARD14/Bcl10 activity. (a) Confocal microscopy analysis of epidermal tissue from ear pinnae from WT and Card14ΔE138+/− mice stained for specific anti-Bcl10, -CARD14, or isotype control antibodies. Nuclei were stained with DAPI. Scale bar = 50 μm. (b–e) Primary murine keratinocytes were isolated from WT and Card14ΔE138+/− tail epidermis and cultured ex vivo for 3–4 days. (b) Cells were lysed in Triton-X–containing buffer, and soluble and insoluble fractions were subject to SDS-PAGE followed by immunoblotting with indicated antibodies. (c) Cell lysates were immunoprecipitated with an anti-Bcl10 antibody, followed by immunoblotting with indicated antibodies. ΔE = keratinocytes from Card14ΔE138+/− mice. (d) Cells visualized for expression and localization of endogenous murine Bcl10 by confocal microscopy using a specific anti-Bcl10 antibody. Nuclei were stained with DAPI. Scale bar = 15 μm. (e) RNA was extracted from whole ear tissue of 5-week-old mice and subjected to quantitative PCR.
mice harbors a pronounced infiltrate of CD45-positive leukocytes (Figure 5a). This immune infiltrate is composed of increased numbers of neutrophils, myeloid antigen-presenting cells, and γδ and αβ T cells compared with WT littermates (Figure 5b, and see Supplementary Figure S5 online). T helper (Th) 17 cells play a central role in psoriatic pathogenesis, and IL-23 maintains the differentiation of pathogenic Th17 cells, which secrete IL-17A and IL-22, two of the cytokines that mediate the inflammatory effects and hyperproliferation associated with human psoriasis (Cai et al., 2012). Indeed, protein levels of IL-17A and IL-22 were significantly increased in Card14E138+/− ear tissue of adult mice (Figure 5c). IL-23p19, IL-17A, and IL-22—encoding transcripts were also seen at significantly higher levels in 5-week-old Card14E138+/− mouse skin (Figure 5d). Similarly, the Th1 cytokines IFNγ and TNF-α were also significantly elevated in ear tissue of 5-week-old Card14E138+/− mice (Figure 5e), contributing to an inflammatory milieu typical of human psoriasis.

To assess whether CARD14-induced psoriatic disease symptoms can be attenuated in vivo by targeted disruption of the IL-23/Th17 axis, Card14E138+/− heterozygous mice were treated with a neutralizing antibody specific for the murine IL-23p19 subunit by intraperitoneal injection over the course of 15 days, and control mice were administered an IgG isotype antibody. Mice receiving anti-IL-23p19—neutralizing antibody showed a significantly decreased psoriatic phenotype on the ears and tail after 2 weeks of therapy (Figure 5f) and a significant reduction in ear thickness versus at the onset of treatment and versus IgG control animals (Figure 5g). Further reductions were evident after administration of IL-23p19 over 3 weeks (see Supplementary Figure S6a–c online). Histological features were assessed by the scoring system of Baker et al. (1992), and IL-23p19−treated mice showed a significant decrease in murine clinical score (Figure 5h and i). In vivo blockade of IL-23p19 also reduced expression of mRNA encoding β-defensins, S100 proteins, IL-36γ, and IL-19 (Figure 5i). These results indicate that disruption of the IL-23/Th17 immune signaling axis is sufficient to reverse the aberrant epidermal signaling networks induced by CARD14 GoF mutation. Thus, CARD14 GoF drives IL-23−mediated psoriatic skin disease, and targeting of IL-23p19 in this mouse model is a rapid and effective therapeutic option, consistent with reports from phase III clinical trials in patients with plaque-type psoriasis (Nakamura et al., 2017; Papp et al., 2017; Reich et al., 2017).

**DISCUSSION**

Psoriasis is a common but complex inflammatory skin disease that arises from the interplay between stress or trauma within the epidermis and a dysregulated immune response. Genetic studies have shown a role for selected genes, particularly those of the innate and adaptive immune system and the IL-23/IL-17 signaling axis (Tsoi, 2012). Several genes encoding proteins in epithelial barrier function have also been linked to psoriasis susceptibility, and GoF mutations in the gene encoding the keratinocyte signaling molecule, CARD14, have been associated with both psoriasis and PRP, although the extent to which CARD14 genetic variants contribute to disease susceptibility is currently unclear.

Here, we unequivocally show that CARD14 GoF alone is sufficient to drive disease pathogenesis in vivo and show that a single amino acid mutation of a key glutamic acid (E138) results in the complete immunological and clinical phenotype of plaque-type psoriasis in mice. The etiology of psoriasis has been elusive in the past, regarding the contribution of keratinocyte dysfunction versus altered immune function (Bos et al., 2005; Christophers, 1996). However, our data strongly suggest that dysregulated keratinocyte signaling pathways initiated by CARD14 contribute to drive the pathogenic IL-23/IL-17 axis in vivo. Card14E138 heterozygous mice spontaneously and rapidly developed a chronic psoriatic phenotype with scaling skin lesions, epidermal acanthosis, parakeratosis, and hyperkeratosis, keratinocyte hyperproliferation, and immune cell infiltration of lesional skin. In addition to Card14E138+/− tissue recapitulating the histological features of psoriasis, transcriptome profiling from affected skin in these mice correlated with up-regulated and down-regulated gene signatures observed in human plaque psoriasis. In particular, high expression of antimicrobial peptides (β-defensins, S100 proteins), chemokines (Ccl20, Ccl22), and cytokines (including IL-19, IL-36γ, IL-1β, and IL-23p19) were observed. Additionally, neutralization of IL-23p19 significantly reduced skin lesions and the expression of anti-microbial peptides and proinflammatory cytokines in the skin of Card14E138 mice.

Tanaka et al. (2018) recently showed that CARD14-deficient mice were protected from developing imiquimod-induced psoriasiform disease (Tanaka et al., 2018), which is consistent with our results that GoF mutation in CARD14 is sufficient to drive the complete immunopathogenesis of psoriatic disease in vivo. Tanaka’s study shows a role for CARD14-positive hematopoietic cells in imiquimod-induced psoriasiform disease. In our study, keratinocytes harboring mutant CARD14 contribute to disease pathogenesis; however, it will be of interest to further tease out the interplay of these different cell types in disease pathogenesis. Taken together, these reports place CARD14 in a central role of mediating psoriatic skin disease pathogenesis, which warrants further clinical appraisal. The physiological relevance to human disease means that the Card14E138+/− mouse model will become an invaluable tool for dissecting the complex signaling networks associated with psoriatic skin disease. This model will also be beneficial in the preclinical assessment of therapeutics aimed at specifically targeting molecular drivers of psoriasis and PRP in the future. These findings highlight the formation of the CARD14/Bcl10/Malt1 complex as a key cellular process to target in the development of future therapies for psoriatic disease. Malt1-specific inhibitors have been suggested as a potential therapeutic strategy that can be used for treating psoriatic skin disease, because inhibition of Malt1 function would have the benefit of identifying the CARD14 mutation with potential for therapeutic intervention.
**Figure 5.** Immune cell infiltrate shows a T helper type 17 signature, and IL-23p19 neutralization ameliorates the phenotype in Card14ΔE138+/– mice. (a, b) Flow cytometry analysis of single-cell suspension from ear tissue from age- and sex-matched adult Card14ΔE138+/– mice and littermate controls. Shown are the number of (a) CD45+ hematopoietic cells and (b) neutrophils (CD11b+Ly6G+), inflammatory (CD11b+Ly6G+NK1.1+MHCIIhiLy6Chi) and noninflammatory (CD11b+Ly6G+NK1.1+MHCIIshLy6C-) APCs, αβ T cells (CD3lowTCRB+), and γδ T cells (CD3lowTCRB+) per ear. (c) Whole ears from age- and sex-matched adult Card14ΔE138+/– and wild-type mice were homogenized and analyzed for IL-17A and IL-22 protein levels by ELISA (n = 8). (d, e) RNA was extracted from whole ear tissue of 5-week-old mice and subjected to quantitative PCR analysis of (d) Il23p19, Il17a, and Il22 or (e) Ifng (IFNγ) and Tnfa mRNA expression...
of affecting T-cell and keratinocyte function (downstream of CARD11 and CARD14, respectively) (Van Nuffel et al., 2017). Targeting CARD14 directly, however, may permit the development of more specific therapies with decreased adverse effect profiles, and this merits further investigation into understanding CARD14 biology.

**MATERIALS AND METHODS**

Details of the materials and methods are given in the Supplementary Materials online.

**Genetically modified mouse strains**

To generate Card14ΔE138 mice, C57BL/6J (JR 000664) oocytes were microinjected with Cas9 mRNA and donor DNA along with one of two guide RNA sequences. Two strains harboring the Card14ΔE138 deletion were generated from separate founder animals, strains 28900 (C57BL/6J-Card14em9(delE138)Lutzy/TY) and 28882 (C57BL/6J-Card14em5(delE138)Lutzy/TY). Mouse strain 28900 was used for the experiments described in the article. All animal experiments were performed in accordance with the regulations and guidelines of and with ethical approval from the Cantonal Veterinary Office of Zürich, Switzerland.

**Cell culture**

Human primary keratinocytes were cultured as previously described (Feldmeyer et al., 2007). Briefly, human primary foreskin keratinocytes were passaged in keratinocyte serum-free medium (Thermo Fisher Scientific, Waltham, MA), supplemented with epithelial growth factor and bovine pituitary extract (Thermo Fisher Scientific, Waltham, MA), and were subjected to a two-tailed unpaired Student t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. AP: antigen-presenting cell; WT, wild type.

**REFERENCES**


**ORCID**

Mark Mellett: http://orcid.org/0000-0002-6315-167X

**CONFLICT OF INTEREST**

The authors state no conflict of interest.

**ACKNOWLEDGMENTS**

The authors thank D. Kazakov, L. Opitz, M. Comazzi, B. Henriques, C. Decaillot, E. Härtel, T. Koch, E. Guenova, G. Fenini, S. Grossi, and H.D. Beer for technical assistance and expertise and Burkhard Becher (University of Zürich), Jeremy Di Domizio, and Michel Gilliet (University Hospital of Lausanne, CHUV) for critical analysis of the manuscript. MM thanks the University of Zürich Forschungskredit, the Swiss Life Jubiläumsstiftung, the European Union-funded Marie Skłodowska-Curie Individual Fellowship for financial support, and the Rare Genomics Institute BeHEARD Science Challenge and the Jackson Laboratories (particularly A. Zuberi and C. Lutz) for the generation of the Card14ΔE138 mouse strains. MT acknowledges support from the Swiss National Science Foundation and the Emma Muschamp Foundation. EC and LEF are supported by grants from the Swiss National Science Foundation (grant number 310030-156384) and Zürich University Research Priority Program (URPP) Translational Cancer Research.

**AUTHOR CONTRIBUTIONS**

MM conceived the study and mouse models, developed the concept, designed and performed experiments, analyzed the data, co-supervised the project and wrote the manuscript. BM designed and performed immunohistochemistry experiments and analysis. DM performed flow cytometry and analysis. RS performed the fluorescence resonance energy transfer assay and subsequent flow cytometry, immunoblotting and data analysis. PC analyzed the RNA sequencing transcriptomic data, BK performed immunohistochemistry experiments, TS and SN contributed critical analysis and experimental design. MT and EC designed experiments, provided critical analysis of data and the manuscript. LEF supervised the project, provided critical analysis of data and co-wrote the manuscript.

**SUPPLEMENTARY MATERIAL**

Supplementary material is linked to the online version of the paper at www.jidonline.org, and at https://doi.org/10.1016/j.jid.2018.03.1525.


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/